Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial
Background Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma. We analysed effects of anti-IL-5/anti-IL-5Rα treatment on sel...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2024-11-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/10/6/00374-2024.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841537073157242880 |
|---|---|
| author | Lina Brinkmann Jan Fuge Tobias Welte Hendrik Suhling Nora Drick |
| author_facet | Lina Brinkmann Jan Fuge Tobias Welte Hendrik Suhling Nora Drick |
| author_sort | Lina Brinkmann |
| collection | DOAJ |
| description | Background
Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma. We analysed effects of anti-IL-5/anti-IL-5Rα treatment on self-reported productivity and absenteeism at work in patients with severe eosinophilic asthma.
Methods
In this prospective single-centre study, patients with severe eosinophilic asthma received a questionnaire assessing their actual occupational status and the influence asthma has on their work life, productivity and missed days at work prior to initiation of antibody treatment and after 6 and 12 months of therapy. Among others, the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) was used.
Results
Out of 54 patients with a median age of 60 years, 27 (50%) were employed. In addition to an increase in asthma control and lung function, self-reported productivity increased significantly with a decrease on the WPAI:SHP from 30% (interquartile range (IQR) 20–50%) to 10% (IQR 0–27.5%) under treatment (p=0.001). Furthermore, self-reported missed days at work were reduced from 2 days·month−1 (IQR 1.75–6 days·month−1) to 0 days·month−1 (IQR 0–2 days·month−1; p=0.067). At baseline 22 employed patients (81%) stated they were affected at work by their asthma. After 12 months of treatment, this number decreased to eight patients (30%; p=0.038).
Conclusions
This prospective analysis could prove the substantial impact severe asthma has on patients’ working life. Anti-IL-5/anti-IL-5Rα treatment in patients with severe eosinophilic asthma leads to a significant increase in self-reported productivity at work, and after 12 months of treatment patients state substantially fewer negative effects on their working situation. |
| format | Article |
| id | doaj-art-79a2f8bcaaba48beaf0c1a34ef3b3142 |
| institution | Kabale University |
| issn | 2312-0541 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj-art-79a2f8bcaaba48beaf0c1a34ef3b31422025-01-14T09:50:21ZengEuropean Respiratory SocietyERJ Open Research2312-05412024-11-0110610.1183/23120541.00374-202400374-2024Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trialLina Brinkmann0Jan Fuge1Tobias Welte2Hendrik Suhling3Nora Drick4 Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany Background Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma. We analysed effects of anti-IL-5/anti-IL-5Rα treatment on self-reported productivity and absenteeism at work in patients with severe eosinophilic asthma. Methods In this prospective single-centre study, patients with severe eosinophilic asthma received a questionnaire assessing their actual occupational status and the influence asthma has on their work life, productivity and missed days at work prior to initiation of antibody treatment and after 6 and 12 months of therapy. Among others, the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) was used. Results Out of 54 patients with a median age of 60 years, 27 (50%) were employed. In addition to an increase in asthma control and lung function, self-reported productivity increased significantly with a decrease on the WPAI:SHP from 30% (interquartile range (IQR) 20–50%) to 10% (IQR 0–27.5%) under treatment (p=0.001). Furthermore, self-reported missed days at work were reduced from 2 days·month−1 (IQR 1.75–6 days·month−1) to 0 days·month−1 (IQR 0–2 days·month−1; p=0.067). At baseline 22 employed patients (81%) stated they were affected at work by their asthma. After 12 months of treatment, this number decreased to eight patients (30%; p=0.038). Conclusions This prospective analysis could prove the substantial impact severe asthma has on patients’ working life. Anti-IL-5/anti-IL-5Rα treatment in patients with severe eosinophilic asthma leads to a significant increase in self-reported productivity at work, and after 12 months of treatment patients state substantially fewer negative effects on their working situation.http://openres.ersjournals.com/content/10/6/00374-2024.full |
| spellingShingle | Lina Brinkmann Jan Fuge Tobias Welte Hendrik Suhling Nora Drick Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial ERJ Open Research |
| title | Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial |
| title_full | Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial |
| title_fullStr | Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial |
| title_full_unstemmed | Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial |
| title_short | Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial |
| title_sort | anti interleukin 5 anti interleukin 5 receptor α treatment improves self reported work productivity in patients with severe eosinophilic asthma a prospective cohort trial |
| url | http://openres.ersjournals.com/content/10/6/00374-2024.full |
| work_keys_str_mv | AT linabrinkmann antiinterleukin5antiinterleukin5receptoratreatmentimprovesselfreportedworkproductivityinpatientswithsevereeosinophilicasthmaaprospectivecohorttrial AT janfuge antiinterleukin5antiinterleukin5receptoratreatmentimprovesselfreportedworkproductivityinpatientswithsevereeosinophilicasthmaaprospectivecohorttrial AT tobiaswelte antiinterleukin5antiinterleukin5receptoratreatmentimprovesselfreportedworkproductivityinpatientswithsevereeosinophilicasthmaaprospectivecohorttrial AT hendriksuhling antiinterleukin5antiinterleukin5receptoratreatmentimprovesselfreportedworkproductivityinpatientswithsevereeosinophilicasthmaaprospectivecohorttrial AT noradrick antiinterleukin5antiinterleukin5receptoratreatmentimprovesselfreportedworkproductivityinpatientswithsevereeosinophilicasthmaaprospectivecohorttrial |